$TOVX
Theriva Biologics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000141057823002348 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.321M $212.0K
YoY Change -45.41% -92.06%
% of Gross Profit
Research & Development $4.196M $4.006M
YoY Change 36.68% 55.88%
% of Gross Profit
Depreciation & Amortization $39.00K $36.00K
YoY Change 30.0% 80.0%
% of Gross Profit
Operating Expenses $6.217M $4.218M
YoY Change -15.18% -15.88%
Operating Profit -$4.218M
YoY Change -15.88%
Interest Expense $308.0K $388.0K
YoY Change -0.65% 142.5%
% of Operating Profit
Other Income/Expense, Net $388.0K
YoY Change 140.99%
Pretax Income -$5.909M -$3.830M
YoY Change -15.83% -20.62%
Income Tax -$424.0K -$527.0K
% Of Pretax Income
Net Earnings -$5.485M -$3.303M
YoY Change -1.88% -31.94%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$0.32 -$0.19
COMMON SHARES
Basic Shares Outstanding 17.04M 17.04M
Diluted Shares Outstanding 17.04M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.18M $31.16M
YoY Change -44.54% -38.28%
Cash & Equivalents $23.20M $31.20M
Short-Term Investments
Other Short-Term Assets $2.286M $2.032M
YoY Change -34.69% 0.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables $128.0K $176.0K
Total Short-Term Assets $27.40M $34.77M
YoY Change -39.8% -34.07%
LONG-TERM ASSETS
Property, Plant & Equipment $422.0K $389.0K
YoY Change 22.32% 48.47%
Goodwill $5.700M $5.460M
YoY Change 3.17% 28.35%
Intangibles $19.76M $18.93M
YoY Change 3.16% -5.79%
Long-Term Investments
YoY Change
Other Assets $180.0K $173.0K
YoY Change 50.0% 57.27%
Total Long-Term Assets $27.82M $26.78M
YoY Change 5.6% 3.14%
TOTAL ASSETS
Total Short-Term Assets $27.40M $34.77M
Total Long-Term Assets $27.82M $26.78M
Total Assets $55.22M $61.55M
YoY Change -23.16% -21.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $770.0K $833.0K
YoY Change -15.85% 8.18%
Accrued Expenses $2.995M $5.590M
YoY Change 100.2% 296.17%
Deferred Revenue $906.0K $525.0K
YoY Change
Short-Term Debt $63.00K $65.00K
YoY Change 10.53% 25.0%
Long-Term Debt Due $63.00K $65.00K
YoY Change 5.0% 30.0%
Total Short-Term Liabilities $6.738M $8.743M
YoY Change -4.56% -33.72%
LONG-TERM LIABILITIES
Long-Term Debt $162.0K $150.0K
YoY Change -26.36% -25.0%
Other Long-Term Liabilities $8.622M $8.355M
YoY Change 2.64% 128.28%
Total Long-Term Liabilities $8.784M $8.505M
YoY Change 1.9% 120.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.738M $8.743M
Total Long-Term Liabilities $8.784M $8.505M
Total Liabilities $15.52M $17.66M
YoY Change -10.26% -14.04%
SHAREHOLDERS EQUITY
Retained Earnings -$309.3M -$303.8M
YoY Change 6.3% 6.47%
Common Stock $346.5M $346.3M
YoY Change 0.81% 0.78%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $39.70M $43.88M
YoY Change
Total Liabilities & Shareholders Equity $55.22M $61.55M
YoY Change -23.16% -21.79%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.485M -$3.303M
YoY Change -1.88% -31.94%
Depreciation, Depletion And Amortization $39.00K $36.00K
YoY Change 30.0% 80.0%
Cash From Operating Activities -$6.541M -$2.955M
YoY Change 21.81% -33.6%
INVESTING ACTIVITIES
Capital Expenditures $56.00K $126.0K
YoY Change -37.78% 530.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$56.00K -$126.0K
YoY Change -37.78% 530.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.457M 2.000K
YoY Change -55.71% -99.93%
NET CHANGE
Cash From Operating Activities -6.541M -2.955M
Cash From Investing Activities -56.00K -126.0K
Cash From Financing Activities -1.457M 2.000K
Net Change In Cash -8.054M -3.079M
YoY Change -7.95% 77.98%
FREE CASH FLOW
Cash From Operating Activities -$6.541M -$2.955M
Capital Expenditures $56.00K $126.0K
Free Cash Flow -$6.597M -$3.081M
YoY Change 20.82% -31.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000894158
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
tovx Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
tovx Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12584
dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address Country
EntityAddressCountry
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
417-4364
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TOVX
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17042765
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31160000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41786000
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1399000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2208000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
34767000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
45520000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
389000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
97000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1831000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1199000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18925000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19150000
CY2023Q3 us-gaap Goodwill
Goodwill
5460000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
CY2023Q3 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
76000
CY2022Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
23000
CY2023Q3 us-gaap Assets
Assets
61545000
CY2022Q4 us-gaap Assets
Assets
71861000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
833000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
915000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5590000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1496000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1269000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
2973000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
525000
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
65000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
57000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
461000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8743000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7060000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5935000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
7211000
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
150000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
221000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
413000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1618000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
874000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1546000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1187000
CY2023Q3 us-gaap Liabilities
Liabilities
17661000
CY2022Q4 us-gaap Liabilities
Liabilities
17297000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17762998
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17042765
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15844294
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15124061
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
18000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346312000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343750000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1058000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-679000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303834000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290969000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41150000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61545000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71861000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
212000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2416000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5099000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5612000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4006000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2570000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10115000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8652000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4218000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4986000
us-gaap Operating Expenses
OperatingExpenses
15214000
us-gaap Operating Expenses
OperatingExpenses
14264000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4218000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4986000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15214000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14264000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-40000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
382000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
170000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1127000
us-gaap Investment Income Interest
InvestmentIncomeInterest
197000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
388000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
161000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1134000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
157000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3830000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4825000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14080000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14107000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-527000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-335000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1216000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-867000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3303000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4490000
us-gaap Net Income Loss
NetIncomeLoss
-12864000
us-gaap Net Income Loss
NetIncomeLoss
-13240000
CY2022Q3 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3303000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4830000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12864000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13580000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17042701
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17042701
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15844061
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15844061
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15784685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15784685
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15176927
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15176927
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3303000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4490000
us-gaap Profit Loss
ProfitLoss
-12864000
us-gaap Profit Loss
ProfitLoss
-13240000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-702000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1527000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-379000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2844000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4005000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6017000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13243000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16084000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
126000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
146000
CY2023Q2 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
2156000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
51000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-5084000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
45019000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
135000
CY2023Q3 tovx Stock Issued During Period At Market Offering Value
StockIssuedDuringPeriodAtMarketOfferingValue
1000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
702000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3303000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41150000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65408000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
112000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6599000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-181000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-4273000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68027000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
113000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1442000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-4477000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62221000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
121000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
1464000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-4490000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
56388000
us-gaap Profit Loss
ProfitLoss
-12864000
us-gaap Profit Loss
ProfitLoss
-13240000
us-gaap Share Based Compensation
ShareBasedCompensation
407000
us-gaap Share Based Compensation
ShareBasedCompensation
346000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1216000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-867000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-999000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-244000
tovx Non Cash Lease Expense
NonCashLeaseExpense
283000
tovx Non Cash Lease Expense
NonCashLeaseExpense
137000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1524000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-780000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
54000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-74000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-504000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
883000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-326000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-129000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
271000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-312000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12455000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13714000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
3863000
tovx Repayment Of Long Term Loans From Vendors
RepaymentOfLongTermLoansFromVendors
417000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4305000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
75000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1376000
tovx Proceeds From Issuance Under At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceUnderAtMarketOfferingNetOfIssuanceCosts
2157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2082000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1358000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-109000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-84000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10628000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16745000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67325000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31257000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50580000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31160000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50490000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
97000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
90000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31257000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50580000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
tovx Fair Value Of Contingent Consideration In Business Combination
FairValueOfContingentConsiderationInBusinessCombination
12158000
tovx Fair Value Of Equity Issued As Consideration In Business Combination
FairValueOfEquityIssuedAsConsiderationInBusinessCombination
6599000
tovx Adjustment Of Pre Close Vcn Financing
AdjustmentOfPreCloseVcnFinancing
417000
tovx Goodwill Measurement Period Adjustment
GoodwillMeasurementPeriodAdjustment
-884000
tovx In Process Research And Development Measurement Period Adjustment
InProcessResearchAndDevelopmentMeasurementPeriodAdjustment
810000
tovx Deferred Tax Liability Measurement Period Adjustment
DeferredTaxLiabilityMeasurementPeriodAdjustment
202000
tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31200000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10600000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-3300000
us-gaap Profit Loss
ProfitLoss
-12900000
CY2023Q3 us-gaap Cash
Cash
26100000
tovx Number Of Intangible Assets Generated As Result Of Acquisition
NumberOfIntangibleAssetsGeneratedAsResultOfAcquisition
2
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
807000
CY2023Q3 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
640000
CY2022Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
197000
CY2023Q3 tovx Accrued Vendor Payments
AccruedVendorPayments
347000
CY2022Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
492000
CY2023Q3 tovx Accrued Expenses
AccruedExpenses
5590000
CY2022Q4 us-gaap Goodwill
Goodwill
5525000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-65000
CY2023Q3 us-gaap Goodwill
Goodwill
5460000
CY2023Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6150000
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
10462000
CY2023Q3 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1190000
CY2022Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
2293000
CY2023Q3 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
501000
CY2022Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
418000
CY2023Q3 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
227000
CY2022Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
155000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
114000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
637000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
176000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
87000
CY2023Q3 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
0
CY2022Q4 tovx Amount Receivable From Prior Owner
AmountReceivableFromPriorOwner
144000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2208000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3734000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1348000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1210000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
959000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
865000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
389000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
345000
CY2023Q3 tovx Accrued Expense As Milestone Due To Prior Owner
AccruedExpenseAsMilestoneDueToPriorOwner
3250000
CY2023Q3 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1353000
CY2022Q4 tovx Accrued Expenses
AccruedExpenses
1496000
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
933000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1216000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
206000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87000
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
130000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
100000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1269000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1403000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
539000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.80
CY2020 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
900000
CY2020Q4 tovx Over Allotment Option Period
OverAllotmentOptionPeriod
P45D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1165575
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000000.0
tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price Decrease
PreferredStockConvertibleConversionPriceDecrease
1.22
CY2022 tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634497
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.24
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y9M10D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
71
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
182
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y10D
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3300000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12900000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4800000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13600000
tovx Effect Of Warrant Exercise Price Adjustment
EffectOfWarrantExercisePriceAdjustment
340000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q3 tovx Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
20000
CY2022Q3 tovx Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
97000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2007000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
461000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1546000
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
65000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
150000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
57000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
221000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
65000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
59000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
49000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
32000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10000
CY2023Q3 tovx Long Term Debt.
LongTermDebt.
215000
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2023Q3 tovx Percentage Of Funds To Be Borrowed By Company
PercentageOfFundsToBeBorrowedByCompany
8.5
tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
156000
us-gaap Operating Lease Cost
OperatingLeaseCost
454000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
163000
us-gaap Operating Lease Cost
OperatingLeaseCost
409000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
161000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
654000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
664000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
582000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
368000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2429000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
422000

Files In Submission

Name View Source Status
0001410578-23-002348-index-headers.html Edgar Link pending
0001410578-23-002348-index.html Edgar Link pending
0001410578-23-002348.txt Edgar Link pending
0001410578-23-002348-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230930.xsd Edgar Link pending
tmb-20230930x10q.htm Edgar Link pending
tmb-20230930x10q001.jpg Edgar Link pending
tmb-20230930xex31d1.htm Edgar Link pending
tmb-20230930xex32d1.htm Edgar Link pending
tmb-20230930_def.xml Edgar Link unprocessable
tmb-20230930_cal.xml Edgar Link unprocessable
tmb-20230930_lab.xml Edgar Link unprocessable
tmb-20230930_pre.xml Edgar Link unprocessable
tmb-20230930x10q_htm.xml Edgar Link completed